|
Jan 18
|
Ozempic, Xtandi among next 15 drugs selected for U.S. price talks
|
|
Jan 17
|
Bausch Health Notes Xifaxan 550 mg Selected For Medicare 2nd Round Negotiations
|
|
Jan 17
|
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
|
|
Jan 16
|
Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?
|
|
Oct 9
|
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024
|
|
Oct 9
|
Bausch Health Companies Inc (BHC) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...
|
|
Oct 8
|
Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises
|
|
Sep 30
|
Investor Alert and Limitation Period: Canadian investors that purchased shares of Bausch Health Companies, Inc. listed on the Toronto Stock Exchange need to act
|
|
Sep 23
|
Here's Why Bausch Health Stock Gained 14.7% in a Week
|
|
Sep 19
|
Bausch (BHC) Surges 11.7%: Is This an Indication of Further Gains?
|
|
Sep 17
|
Bausch Health Taps Jefferies to Refinance Debt, Aid Spinoff
|
|
Sep 17
|
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?
|
|
Jul 31
|
Bausch + Lomb (BLCO) Matches Q2 Earnings Estimates
|
|
Jul 31
|
Bausch + Lomb Down 1% In US Premarket As Q2 Adjusted Profit Falls, Even As Revenue Rose; Co Raised 2024 Guidance
|
|
Jul 31
|
Bausch + Lomb: Q2 Earnings Snapshot
|
|
Jul 25
|
Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?
|
|
Jul 24
|
Bausch Health Stock Swings Wildly as it Addresses Report It's Considering Bankruptcy
|
|
Jul 24
|
Bausch Health Responds to Market Rumors
|
|
Jul 24
|
Bausch Health tanks 23.3% on unconfirmed report of bankruptcy filing
|
|
Jul 23
|
Nanotechnology in medicine: Who are the leading public companies?
|